Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLight: phase II tarlatamab in advanced extrapulmonary neuroendocrine carcinoma
KCT0010219Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tarlatamab in extrapulmonary neuroendocrine carcinoma (EPNEC) (2 cohorts), sponsored by Amgen. Primary endpoint: Objective response rate. Started Sep 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on KCT0010219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010219.